Document is current
Any future updates will be listed below
-
Authors
Bellou, Eftychia
Kim, Woori
Leonenko, Ganna
Tao, Feifei
Simmonds, Emily
Wu, Ying
Mattsson-Carlgren, Niklas
Hansson, Oskar
Nagle, Michael W.
Escott-Price, Valentina
,
-
Funding
Funding for this research was provided by:
Medical Research Council (UKDRI-3003, UKDRI-3003, UKDRI-3003)
- License Information
-
More Information
Article History
Received: 8 August 2024
Accepted: 23 December 2024
First Online: 6 January 2025
Declarations
:
: As per ADNI protocols, all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. More details can be found at adni.loni.usc.edu. BioFINDER is approved by the Regional Ethics Committee in Lund, Sweden.
: Not applicable.
: EB was supported jointly by UK-DRI and by Eisai Inc; WK, FT, YW and MWN are employees of the Eisai Inc.OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens.GL, VE-P, ES, NM-C-nothing to declare.
